Yong zeng department of chemistry victaulic t gasket

#########

Quantitative analysis of dynamic and heterogeneous biological processes is key to deciphering complex biological systems, such as cancer. Drawing on microfluidics, analytical chemistry, molecular/cell biology, bioengineering, and material science, our research is dedicated to advancing quantitative biology and personalized medicine through technology innovation and translational research. We currently focus on three main areas:

Quantitative Single Cell Analysis for Cancer Biology and Clinical Medicine. Cancer is a complex genetic disease that derives from single cells gradually accumulating mutations. Early stage carcinogenesis has been challenging to study due to the lack of tools capable of quantitative detection and molecular characterization of low frequency mutations. Most current ortega y gasset revolt of the masses molecular biology methods examine an ensemble average across a large number of cells despite the remarkable molecular heterogeneity of tumor cells. So the ability of molecular analysis with single cell sensitivity and resolution is imperative for a better understanding of cancer biology and for improving clinical medicine.

Single cell analysis represents a new frontier in biology and medicine. Our research in this field focuses on developing high-throughput microfluidic technologies that enable quantitative single cell analysis of genotypic and phenotypic changes associated with cancer at the systems level. We are particularly interested in applying the new technologies to interrogating rare cancer cells of clinical significance, such as minimal residual disease (MRD) responsible for disease recurrence and circulating tumor cells (CTC) associated with metastasis.

High-throughput Glycoproteomics and Glycomics. Protein glycosylation is ubiquitously involved in all aspects of tumor development. While glycoproteins and their carbohydrate modifications (glycans) show great potential for cancer diagnosis and prognosis, progress of glycobiology and clinical utility has been largely hindered due to the complexity of glycome, dynamic nature of glycosylation changes, and the lack of efficient analytical tools. In response to these gas in back relief challenges, our group is interested in exploiting microfluidic platforms to leverage the performance of glycoproteomic and glycomic analysis. Our short-term goal is to develop high-throughput glycomic profiling technologies that enable sensitive quantitation of glycoproteins of interest, structural analysis of glycans, and dynamic mapping of disease-associated glycosylation aberrations using minute blood samples. We are committed to establishing cross-disciplinary collaborations to address the long-term goal– development and clinical validation of glyco-biomarkers and diagnostic devices for early detection of cancer and cancer risk.

Nanomaterial Enabled Bioanalytical Technologies. Rapid advent of life science and global health care calls for the development of novel bioanalytical methodologies and high-performance affordable diagnostic devices. Nanoscale materials, such as nanoparticle and nanowire, are well suited to address this need due to their unique chemical and physical properties. Most of these designer materials, however, are not amenable to monolithic device integration, which significantly restricts their biomedical applications. Our research in this area is oriented to explore gasoline p novel programmable nanomaterial self-assembling techniques and to develop nanomaterial integrated microsystems for high-performance analysis of small molecule drugs, metabolites, and biomarkers. The applications we are interested in encompass forensics, pharmaceutical analysis, and public health care such as point-of-care (POC) diagnostics.

Quantitative analysis of dynamic and heterogeneous biological processes is key to deciphering complex biological systems, such as cancer. Drawing on microfluidics, analytical chemistry, molecular/cell biology, bioengineering, and material science, our research is dedicated to advancing quantitative biology and personalized medicine through technology innovation and translational research. We currently focus on three main areas:

Quantitative Single Cell Analysis for Cancer Biology and Clinical Medicine. Cancer is a complex genetic disease that derives from single cells gradually accumulating mutations. Early stage carcinogenesis has been challenging to study electricity and magnetism study guide 5th grade due to the lack of tools capable of quantitative detection and molecular characterization of low frequency mutations. Most current molecular biology methods examine an ensemble average across a large number of cells despite the remarkable molecular heterogeneity of tumor cells. So the ability of molecular analysis with single cell sensitivity and resolution is imperative for a better understanding of cancer biology and for improving clinical medicine.

Single cell analysis represents a new frontier in biology and medicine. Our research in this field focuses on developing high-throughput microfluidic technologies that enable quantitative single cell analysis of genotypic and phenotypic changes associated gas density calculator with cancer at the systems level. We are particularly interested in applying the new technologies to interrogating rare cancer cells of clinical significance, such as minimal residual disease (MRD) responsible for disease recurrence and circulating tumor cells (CTC) associated with metastasis.

High-throughput Glycoproteomics and Glycomics. Protein glycosylation is ubiquitously involved in all aspects of tumor development. While glycoproteins and their carbohydrate modifications (glycans) show great potential for cancer diagnosis and prognosis, progress of glycobiology and clinical utility has been largely hindered due to the complexity of glycome, dynamic nature of glycosylation changes, and the lack of efficient analytical tools. In response to these challenges, our group is interested in exploiting microfluidic platforms to leverage the performance of glycoproteomic and glycomic analysis. Our short-term goal is to develop high-throughput glycomic profiling technologies that enable sensitive quantitation of glycoproteins of interest, structural analysis of glycans, and dynamic mapping of disease-associated glycosylation aberrations gas constant in kj using minute blood samples. We are committed to establishing cross-disciplinary collaborations to address the long-term goal– development and clinical validation of glyco-biomarkers and diagnostic devices for early detection of cancer and cancer risk.

Nanomaterial Enabled Bioanalytical Technologies. Rapid advent of life science and global health care calls for the development of novel bioanalytical methodologies and high-performance affordable diagnostic devices. Nanoscale materials, such as nanoparticle and nanowire, are well suited to address this need due to their unique chemical and physical properties. Most of these designer materials, however, are not amenable to monolithic device integration, which significantly restricts their biomedical applications. Our research in this area is oriented to explore novel programmable nanomaterial self-assembling techniques and to develop nanomaterial integrated microsystems for high-performance analysis of small molecule drugs, metabolites, and biomarkers. The applications we are interested in encompass forensics, pharmaceutical analysis, and public health care such as point-of-care (POC) diagnostics.